What are Kappa Opioid Receptor Agonist drugs?

Kappa Opioid Receptor Agonist drugs are pharmacologic agents that share a common mechanism (typically targeting Kappa-type opioid receptor). 1 are currently marketed, with 5 more in clinical development.

What are the marketed Kappa Opioid Receptor Agonist drugs?

Marketed Kappa Opioid Receptor Agonist drugs include Korsuva.

Kappa Opioid Receptor Agonist

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 marketed 2 in Phase 3 3 in Phase 2

This page covers all Kappa Opioid Receptor Agonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Kappa-type opioid receptor, Kappa opioid receptor (KOR), Kappa opioid receptor.

Targets

Kappa-type opioid receptor · Kappa opioid receptor (KOR) · Kappa opioid receptor · kappa opioid receptor

Marketed (1)

Korsuva · Vifor Intl · Neuroscience
Korsuva works by activating the kappa-type opioid receptor, which helps to reduce itching.

Phase 3 pipeline (2)

Nalfurafine HCl 5.0 µg · Acologix, Inc. · Dermatology / Nephrology
Nalfurafine is a selective kappa opioid receptor agonist that modulates itch signaling in the central and peripheral nervous system.
Nalfurafine HCl 2.5 µg · Acologix, Inc. · Dermatology
Nalfurafine is a selective kappa opioid receptor agonist that modulates itch signaling in the central and peripheral nervous system.

Phase 2 pipeline (3)

ALC-2203-AC · Korea Arlico Pharm. Co., Ltd · Pain
ALC-2203-AC is a selective and potent agonist of the kappa opioid receptor.
Arm 1: CL-H1T · Charleston Laboratories, Inc · Pain
CL-H1T is a compound that targets the kappa opioid receptor.
AC-203 · TWi Biotechnology, Inc. · Pain
AC-203 is a selective agonist of the kappa opioid receptor.

Patent intelligence

kappa opioid receptor agonist patent landscape — aggregated cliff calendar, attackable patents, originator estates